The role of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma is a subject of debate. We report a durable complete response in a 62-year-old man Jehovah's Witness with metastatic clear cell renal cell carcinoma who received two cycles of nivolumab/ipilimumab followed by radical nephrectomy and metastasectomy of known pulmonary disease site, both without a clinical need for perioperative blood transfusions. The patient continues to be without evidence of disease and without additional need for systemic therapy over a year after his radical nephrectomy. The case highlights that cytoreductive nephrectomy continues to play a role in the era of immune checkpoint inhibitors.
Keywords: TKI (tyrosine kinase inhibitor); cytoreductive; ipilimumab; nivolumab; oligometastatic; renal cell carcinoma.
Copyright © 2022 Zhuang, Harik, Force, Hadadi, Bilen, Brown, Carthon, Goldman, Kucuk, Master and Nazha.